Joining us now, Courtney Breen, senior analyst at Bernstein, covering US Pharma, Bioarma. Courtney, great to have you with us. Um, obviously there's still some some questions outstanding.I'm I'm wondering if you're you know, as you think about companies with US manufacturing, if companies have pre-existing plants, are they also exempt. I think what we've had so far is a a tweet or a post uh on on truth social rather than necessarily the discreet and detailed policy. So I think there are a lot of questions t ...

税务争议解决 - 公司与加拿大税务局就2013至2019税务年度转移定价重新评估达成最终和解 [1] - 和解无需就巴巴多斯和墨西哥子公司的境外收入在加拿大补缴税款 [7] - 转移定价相关罚款将被撤销 利息费用将相应调整减少 [7] 服务费调整 - 对子公司提供服务的收费加成率从当前7-20%提高至30% [7] - 调整导致公司需在加拿大就140万加元额外收入纳税 [7] - 通过非资本损失抵扣后 预计不会产生实际现金税负 [7] 战略影响 - 解决税务争议为全球扩张计划提供更明确投资确定性 [3] - 公司过去18个月完成约30亿美元交易以扩充优质长寿命资产组合 [3] - 和解确立的定价原则预计将延续至2019年后税务年度 [7] 公司背景 - 公司为全球领先的黄金权利金与流交易企业 拥有最多元化现金流资产组合 [5] - 商业模式提供金价上涨及勘探期权优势 同时规避成本通胀风险 [5] - 自由现金流用于组合扩张及股息分配 在多伦多及纽约交易所上市代码FNV [5]